Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HEXA | P06865 | 1/20 | 0.44 |
| ▸ | HEXB | P07686 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 3/20 | 0.43 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | ADK | P55263 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1882625 | 0.77 | MAP4K4 (0.57) | HEXAHEXBDHFR | |
| SCHEMBL12368259 | 0.77 | HEXA (0.68) | HEXAHEXBDHFR | |
| SCHEMBL4530128 | 0.75 | IKBKB (0.55) | HEXAHEXBDHFR | |
| SCHEMBL19698856 | 0.74 | PNPLA2 (0.56) | PNPLA2HDAC6AOC3 | |
| Hydrochloric Acid SCHEMBL4532657 | 0.74 | HEXA (0.48) | HEXAHEXBDHFR | |
| SCHEMBL3500167 | 0.73 | DHFR (0.61) | HEXAHEXBDHFR | |
| SCHEMBL6049535 | 0.73 | IKBKB (0.56) | HEXAHEXBDHFR | |
| SCHEMBL14065149 | 0.71 | PNPLA2 (0.53) | PNPLA2HDAC6AOC3 | |
| SCHEMBL12368257 | 0.70 | HEXA (0.64) | HEXAHEXBDHFR | |
| SCHEMBL1885367 | 0.70 | HEXA (0.50) | HEXAHEXBDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | ASTERAND UK LIMITED (GB) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018150-A1 | 5-Ht2b Receptor Antagonists | HTR2B, HTR1B, HTR3B | HEXA 748/4885HEXB 352/4885DHFR 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.